EGFR and non-small cell lung carcinoma: Most patients with advanced NSCLC receiving EGFR-TKIs experience drug-related toxicities where acneiform is the common complaint.[10] Multiple versions of guidelines of management[1,11–14] of this kind of rash are accessible, whereas most are developed based on evidence from single-arm trials, expert consensus, case reports or retrospective cohort studies.[15] The efficacy of those interventions recommended to prevent or reduce acneiform still remains unclear.